Business Wire

NIKON-EUROPE

5.10.2021 06:02:13 CEST | Business Wire | Press release

Share
Nikon’s First European Nikon BioImaging Lab Now Open in Leiden

Nikon Europe B.V. has announced that its first European Nikon BioImaging Lab (NBIL) based in the prestigious Leiden Bio Science Park (LBSP) is now officially open.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211004005909/en/

The official opening took place on September 22nd with a welcome by Ziryan Othman, Team Leader Biotechnology Solutions, Nikon Europe Healthcare Division, followed by addresses by representatives of the organisations involved in helping Nikon Europe B.V. locate and develop the partnership with the Leiden Bio Science Park: Paul Dirkse, Vice Mayor of the City of Leiden; Hilde van der Meer, Commissioner, Netherlands Foreign Investment Agency; Chris van Voorden, Director Foreign Investments of InnovationQuarter; Ida Haisma, Director of Stichting Leiden Bio Science Park; Thijs de Kleer, Director of Biopartner Leiden, and Amito Haarhuis, Director of Rijksmuseum Boerhaave. Bo Kajiwara, Corporate Vice President, Nikon Corporation, Director & President, Nikon Europe B.V. led the opening program for Nikon Europe B.V.

The inauguration and ribbon cutting took place with a symbolic transfer of the famous 17th century van Leeuwenhoek’s microscope, by Amito Haarhuis. World famous for his pioneering work and discoveries in microscopy, Antonie van Leeuwenhoek developed this single-lens microscope, which proved capable of more powerful magnification than other lenses.

Takaharu Sasaoka, Director and Executive Vice President, Healthcare Business Head, Nikon Europe B.V., appreciates the symbolism of the microscope transfer, “It is very appropriate that Nikon, with over 100 years of expertise in optical technology, should open its first European Nikon BioImaging Lab (NBIL-Leiden) here in the Netherlands, the home of Antonie van Leeuwenhoek, the ‘father of microbiology’, whose systematic and extensive research laid the foundations of medical and scientific research. Our mission also is to advance healthcare and provide a better quality of life.

“We are very excited to be located here in the Leiden Bio Science Park, the largest life sciences cluster in the Netherlands, and I would like to thank all the organisations that helped Nikon Europe B.V. locate and develop this partnership. Following the success of our Nikon BioImaging Labs in the US and Japan, NBIL-Leiden will provide services for microscope-based imaging and analysis to the European biotech, pharma, and larger research communities. We are more than a core facility – our full-service capabilities include not only access to Nikon’s innovative microscopy instrumentation and software, but also the services of expert biologists and microscopists, who are available to provide quality cell culture, sample preparation, data acquisition, and data analysis services.”

Daniel Ciepielewski, General Manager, Healthcare Division, Nikon Europe B.V., explains further, “NBIL-Leiden provides full-service imaging, data analysis, and cell cultures using cutting-edge Nikon microscope systems and software solutions, including the new laser scanning confocal AX R, the incubated high content imaging platform LIPSI, deep learning software NIS.ai, research inverted microscope Ti2-E, and compact live-cell imaging microscope BioStudio-T. Unlike other imaging facilities the lab offers full-service cell culture capabilities – our experienced staff is equipped to handle cell thawing, maintenance, expansion, differentiation, and other essential operations.

“The level of service and involvement of the lab is determined individually for each client based on need. Some need only access to equipment and are capable of data acquisition/analysis on their own, while others may require full-service imaging and analysis support. Additional applications include high content imaging and analysis, 3D imaging, fluorescence imaging, high-resolution imaging, color imaging, label-free imaging, cell screening and high throughput imaging, among others. NBIL-Leiden is now open, providing expert imaging support – on demand.”

Nikon Europe B.V. is grateful to InnovationQuarter, the regional economic development agency for the Province of Zuid-Holland, which assisted us in finding the right location and helped coordinate communication to develop the partnership with the Leiden Bio Science Park.

Nikon Europe B.V. is also grateful to the following contributing companies who have partnered with NBIL-Leiden: Clean Air Baker, PHC, Crest Optics, Photometrics, CoolLed, and Precipoint.

For further information, please contact: NBIL.EU@nikon.com
Or please visit www.microscope.healthcare.nikon.com/en_EU/products/cell-screening/nbil .

About Nikon Europe B.V.
Nikon Europe B.V. is the European microscopy arm of Nikon Healthcare Business Unit, a world leader in the development and manufacture of optical and digital imaging technology for biomedical applications. For more information, please visit www.microscope.healthcare.nikon.com/en_EU .

Link:

ClickThru

Social Media:

https://www.facebook.com/nikoninstrumentsinc

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Imagine Dragons to Perform at Abu Dhabi Grand Prix21.5.2026 17:51:00 CEST | Press release

Ethara, organiser of the Formula 1 Etihad Airways Abu Dhabi Grand Prix, have announced that one of the world’s biggest bands, Imagine Dragons, will headline the Saturday After-Race Concerts at the F1 Season Finale in Abu Dhabi. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521214839/en/ Imagine Dragons to perform at Formula 1 Etihad Airways Abu Dhabi Grand Prix (Photo: AETOSWire) The announcement is another landmark moment for the Abu Dhabi Grand Prix, whose thrilling Yasalam presented by e& fan entertainment offering has become synonymous with the F1 Championship finale in Abu Dhabi and is recognised as one of the most compelling sports and entertainment crossovers globally. The global chart-toppers join Lewis Capaldi and Zara Larsson, who are set to kick off a blockbuster line-up of performances on Yas Island on Thursday, 3 December, with more major international artists to be revealed. With their popular top hits, Ima

Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release

Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d

Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 14:00:00 CEST | Press release

A growing wave of unsupported solar systems and rising electricity prices are creating strong demand for Otovo’s energy service platform Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensu

The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release

New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r

Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release

Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye